<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976948</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9551</org_study_id>
    <nct_id>NCT02976948</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Sequencing Strategy in Autoinflammatory Siseases (BIOSAID)</brief_title>
  <acronym>BIOSAID</acronym>
  <official_title>Evaluation of a New Sequencing Strategy in Autoinflammatory Diseases Diagnostic Value and Therapeutic Orientation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: To compare the efficacy of a new strategy of Next Generation Sequencing (NGS)&#xD;
      versus a classical Sanger strategy, for the diagnosis of patients referred to the laboratory&#xD;
      for suspected systemic autoinflammatory diseases (SAID).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Compare after 6 months the impact of these strategies on the establishment of an&#xD;
           effective treatment SAID following genetic result.&#xD;
&#xD;
        -  Compare the distribution of different forms of SAID found with each genetic diagnostic&#xD;
           strategies (NGS vs classic method).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic autoinflammatory diseases (SAID) include a broad spectrum of pathologies of innate&#xD;
      immunity. In recent years, numerous publications have shown the involvement of new genes in&#xD;
      these diseases, highlighting new pathophysiological pathways (inflammasome, NFkB: nuclear&#xD;
      factor-kappa B, interferon) and new targeted therapies (biotherapy advantageously replacing&#xD;
      non-specific anti-inflammatory drugs). Current laboratory diagnostic strategy is based on the&#xD;
      Sanger method, the gold standard to date, allowing the sequential analysis of some genes&#xD;
      (usually between 1 and 4). The nonspecific nature of the clinical presentation of these&#xD;
      diseases, the increasing number of genes involved and the low diagnostic yield obtained, make&#xD;
      it essential to develop a new strategy, more efficient, so that the patient can benefit as&#xD;
      soon as possible treatment suited to his pathology as soon as the gene involved is&#xD;
      identified. The investigator had developed and validated in our genetic laboratories a new&#xD;
      method based on the Next Generation Sequencing (NGS). A panel of 32 known or candidate SAID&#xD;
      genes, which can be simultaneously analyzed within a time compatible with the diagnosis. The&#xD;
      investigator wishes to highlight the benefits of this new strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2015</start_date>
  <completion_date type="Actual">July 17, 2018</completion_date>
  <primary_completion_date type="Actual">January 17, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of genetically ascertained patients using Next Generation Sequencing (NGS) vs Sanger</measure>
    <time_frame>At time of report issue up to two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Date of introduction of relevant treatment</measure>
    <time_frame>6 months after report issue</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">299</enrollment>
  <condition>Systemic Autoinflammatory Diseases (SAID)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients with prerequisites established jointly by the reference centers . At least 3&#xD;
      unexplained inflammatory access elevated CRP (C reactive protein)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to the laboratory for suspected Systemic Autoinflammatory Diseases (SAID)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with prerequisites established jointly by the reference centers:&#xD;
&#xD;
          -  At least 3 unexplained inflammatory access&#xD;
&#xD;
          -  Elevated C Reactive Protein&#xD;
&#xD;
          -  Age of symtoms less than 30 years and validated by a physician CeréMAI (Centre de&#xD;
             référence des maladies autoinflamatoires)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other inflammatory disease:&#xD;
&#xD;
          -  intercurrent infection&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume SARRABAY, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>university Hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

